source
- Altimmune's pemvidutide cuts heavy drinking days in Phase 2 trialAltimmune reported that its experimental GLP-1/GIP injection pemvidutide achieved its primary and key secondary goals in a Phase 2 study of alcohol use disorder. The double-blind trial enrolled 10…
- Claris Bio secures $118 million to launch pivotal eye-drop trials next yearClaris Bio announced a financing round that raised $118 million to move its investigational eye‑drop therapy forward. The capital will fund two pivotal Phase 3 studies slated to start next year, f…